These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 11454684

  • 1. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG.
    Cancer Res; 2001 Jul 15; 61(14):5407-14. PubMed ID: 11454684
    [Abstract] [Full Text] [Related]

  • 2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999 Jul 15; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

  • 3. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
    Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA.
    Clin Cancer Res; 2003 Apr 15; 9(4):1253-8. PubMed ID: 12684392
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
    Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG.
    Cancer; 2003 Nov 15; 98(10):2125-32. PubMed ID: 14601081
    [Abstract] [Full Text] [Related]

  • 5. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb 15; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 7. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.
    Br J Cancer; 1999 Feb 15; 79(5-6):888-94. PubMed ID: 10070886
    [Abstract] [Full Text] [Related]

  • 8. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA, Romain S, Look MP, Martin PM, Klijn JG.
    Cancer Res; 2001 Feb 15; 61(4):1421-5. PubMed ID: 11245445
    [Abstract] [Full Text] [Related]

  • 9. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
    Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J.
    Cancer Res; 2001 Mar 01; 61(5):2256-60. PubMed ID: 11280795
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.
    Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE.
    Cancer Res; 2000 Jun 01; 60(11):2898-905. PubMed ID: 10850435
    [Abstract] [Full Text] [Related]

  • 11. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
    Wu Y, Saldana L, Chillar R, Vadgama JV.
    Int J Oncol; 2002 Mar 01; 20(3):509-16. PubMed ID: 11836562
    [Abstract] [Full Text] [Related]

  • 12. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G.
    Breast Cancer Res Treat; 2005 Jan 01; 89(2):135-43. PubMed ID: 15692755
    [Abstract] [Full Text] [Related]

  • 13. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L, Jirström K, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE, Landberg G.
    J Clin Oncol; 2005 Jul 20; 23(21):4695-704. PubMed ID: 16034044
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB.
    Clin Cancer Res; 2006 Aug 01; 12(15):4562-8. PubMed ID: 16899602
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
    Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H, Moneer MM.
    Clin Biochem; 2009 Sep 01; 42(13-14):1420-6. PubMed ID: 19576877
    [Abstract] [Full Text] [Related]

  • 16. The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
    Wen XF, Shen Z, Shen ZZ, Nguyen M, Shao ZM.
    Oncol Rep; 2002 Sep 01; 9(5):937-44. PubMed ID: 12168051
    [Abstract] [Full Text] [Related]

  • 17. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.
    Sanchez BC, Sundqvist M, Fohlin H, Spyratos F, Nordenskjöld B, Stål O, Linderholm BK.
    Eur J Cancer; 2010 Jun 01; 46(9):1580-7. PubMed ID: 20413297
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI.
    J Clin Oncol; 2010 Feb 10; 28(5):723-30. PubMed ID: 20026801
    [Abstract] [Full Text] [Related]

  • 19. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.
    Clin Cancer Res; 2000 Jul 10; 6(7):2751-8. PubMed ID: 10914720
    [Abstract] [Full Text] [Related]

  • 20. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2005 Oct 15; 11(20):7311-21. PubMed ID: 16243802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.